This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Idorsia Pharmaceuticals Ltd. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Alexia Chavanton-Arpel: Innovator in CCR6 Receptor Modulation
Introduction
Alexia Chavanton-Arpel is a notable inventor based in Allschwil, Switzerland. She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific receptors in the body.
Latest Patents
Her most recent patent is titled "Azetidin-3-ylmethanol derivatives as CCR6 receptor modulators." This invention relates to compounds of Formula (I), their synthesis, and their use as CCR6 receptor modulators for the treatment or prevention of various diseases, conditions, or disorders. This patent highlights her innovative approach to addressing complex health issues.
Career Highlights
Alexia is currently employed at Idorsia Pharmaceuticals Ltd., where she continues to advance her research and development efforts. Her work is instrumental in the pharmaceutical industry, contributing to the creation of new therapeutic options.
Collaborations
She collaborates with esteemed colleagues, including Eva Caroff and Oliver Allemann, who share her commitment to innovation in the pharmaceutical sector.
Conclusion
Alexia Chavanton-Arpel exemplifies the spirit of innovation in the pharmaceutical industry through her groundbreaking work on CCR6 receptor modulators. Her contributions are paving the way for new treatments and improving patient outcomes.